Shire Expects Next-Generation Adderall XR Approval Following DEA Scheduling
This article was originally published in The Pink Sheet Daily
Executive Summary
"Approvable" letter from FDA says marketing approval of NRP-104 is contingent upon final scheduling by DEA.